“Highlights of May’s Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a new analysis of dietary factors and risks for age-related macular degeneration (AMD), and a landmark study on glaucoma …
Highlights of May’s Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a new analysis of dietary factors and risks for age-related macular degeneration (AMD), and a landmark study on glaucoma treatment cost-effectiveness as linked to vision improvement and quality of life.
SAN FRANCISCO, CA— Highlights of May’s Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a new analysis of dietary factors and risks for age-related macular degeneration (AMD), and a landmark study …
After a comprehensive review of the scientific literature available, Lucentis and Macugen have been endorsed by the American Academy of Ophthalmology as safe and effective treatments for macular degeneration for up to 2 years. In the endorsement it was indicated that there is evidence to support that Macugen and Lucentis as effective treatments. However, there was no endorsement given for Avastin as a treatment for macular degeneration at this time.
Ophthalmology This month, the Journal of the American Academy of Ophthalmology (Academy) reports on a national study finds, the cataract surgery is likely in patients with age-related macular degeneration (AMD) in all phases of the …
